EntreMed cancer drug deemed safe
Pharmaceutical Business Review - EntreMed has revealed that an an independent Data Safety Monitoring Board has conducted a favorable review of safety data from its breast cancer drug. The review was undertaken to assess the safety of the drug, MKC-1 in a phase II trial in patients
Source: www.pharmaceutical-business-review.com
Click here for more information about treating depression treating depression
